Safety, treatment delivery, and pathological response before and after pembrolizumab implementation for early ER-negative, HER2-normal breast cancer.
- DOI
- 10.1016/j.esmorw.2026.100769
- Published
- 2026 Sep
- Container
- ESMO real world data and digital oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.esmorw.2026.100769,
title = {Safety, treatment delivery, and pathological response before and after pembrolizumab implementation for early ER-negative, HER2-normal breast cancer.},
author = {Henriksen AF and Lundgren ANH and Andersen MA and Gerds TA and Knop AS and Petersen TS and Lassen U and Bjerrum A},
year = {2026},
journal = {ESMO real world data and digital oncology},
doi = {10.1016/j.esmorw.2026.100769},
url = {https://doi.org/10.1016/j.esmorw.2026.100769}
}RIS
TY - JOUR TI - Safety, treatment delivery, and pathological response before and after pembrolizumab implementation for early ER-negative, HER2-normal breast cancer. AU - Henriksen AF AU - Lundgren ANH AU - Andersen MA AU - Gerds TA AU - Knop AS AU - Petersen TS AU - Lassen U AU - Bjerrum A PY - 2026 JO - ESMO real world data and digital oncology DO - 10.1016/j.esmorw.2026.100769 UR - https://doi.org/10.1016/j.esmorw.2026.100769 ER -
APA
AF, H., ANH, L., MA, A., TA, G., AS, K., TS, P., U, L., & A, B. (2026). Safety, treatment delivery, and pathological response before and after pembrolizumab implementation for early ER-negative, HER2-normal breast cancer.. ESMO real world data and digital oncology. https://doi.org/10.1016/j.esmorw.2026.100769
Source records
- pubmed · retrieved 2026-09-27T01:08:47.525Z